Cognition Is Associated With Peripheral Immune Molecules in Healthy Older Adults: A Cross-Sectional Study

Abstract

Background Cognition in the elderly is heterogeneous. Senescence of the immune system is increasingly considered as a potential player in cognitive performance. We explored here the interplay between cognitive performance and peripheral immune molecules in healthy older individuals. Methods A cross-sectional study of clinically well characterized senior healthy individuals (120; 51–87 years old) previously clustered as “Good” and “Poor” performers based on established tests that evaluate memory and executive function. A plasma concentration of 30 immune molecules was assessed by multiplex analysis and correlated with parameters of cognitive performance. Results Participants with worse cognitive performance (“Poor”) exhibited increased concentrations of IL-1β, IL-8, IL-13, and tumor necrosis factor (TNF) when compared to individuals with a better cognitive performance (“Good”). The cognitive dimensions memory and executive function, when considered separately, displayed a negative association with several immune molecules (IL-1β, IL-1RA, IL-6, IL-13, IP-10, and TNF with memory and only IL-1β with executive function), even controlling for age, sex, years of formal education, mood, and use of anti-inflammatory drugs. Regression analysis showed that several of these molecules (IL-1β, IL-6, IL-8, and IL-13) contribute to predicting whether an individual belongs to the “Good” or “Poor” cognitive performance group. Conclusion These results strengthen the hypothesis that increased concentrations of peripheral immune molecules, like IL-1β, are associated with worse cognitive performance in senior healthy individuals. It further highlights that some poorly studied immune molecules should be considered in the context of cognitive aging, such as IL-13, here revealed as a new player in such interaction.

Association of lower liver function with cognitive impairment in the Shenzhen ageing-related disorder cohort in China

“…Interestingly, our finding revealed a lower ALB level in the cognitive impairment group compared to the normal cognition group (44.1 [42.7, 45.68] vs. 44.6 [43.4, 45.9] g/L, p = 0.001; Table 1 ). This is concordant with results from the Longitudinal Aging Study Amsterdam, in which an association between low serum ALB and cognitive function decline was observed in 1,284 older individuals ( Serre-Miranda et al, 2020 ). Moreover, a recent study showed that intravenous supplementation with human ALB improved daily function and reduced dementia burden in patients with AD ( Zhong et al, 2020 ).…”

Systemic inflammatory markers in relation to cognitive function and measures of brain atrophy: a Mendelian randomization study

“…Systemic inflammation has been hypothesized as a risk factor in cognitive decline and dementia [5][6][7][8]. Epidemiological studies have identified associations of elevated systemic inflammation levels and worse cognition in cross-sectional studies, and a steeper cognitive decline in prospective studies [9,10]. Moreover, anti-inflammatory therapy, particularly nonsteroidal anti-inflammatory drugs (NSAIDs), has been associated with a lower risk of cognitive decline in a meta-analysis of observational cohort studies [11].…”

Innate Immune System Activation and Neuroinflammation in Down Syndrome and Neurodegeneration: Therapeutic Targets or Partners?

“…Many studies have shown that both people with DS and typical aging adults exhibit an auto-inflammatory or “inflammaging” syndrome (Trollor et al, 2012 ; Frasca and Blomberg, 2016 ; Ashraf-Ganjouei et al, 2020 ; Serre-Miranda et al, 2020 ) that might predict that GM-CSF treatment would be detrimental. However, GM-CSF is not merely a pro-inflammatory molecule.…”